Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
23Andme Holding Co.
(NQ:
ME
)
0.3228
-0.0113 (-3.38%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about 23Andme Holding Co.
< Previous
1
2
3
Next >
23andMe Reports First Quarter Fiscal 2025 Financial Results
August 08, 2024
From
23andMe, Inc.
Via
GlobeNewswire
23andMe Special Committee responds to CEO’s take-private proposal
August 02, 2024
From
23andMe, Inc.
Via
GlobeNewswire
23andMe Announces CEO’s Take-Private Proposal
August 01, 2024
From
23andMe, Inc.
Via
GlobeNewswire
23andMe to Report Q1 FY2025 Financial Results
July 25, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research
July 25, 2024
Study aims to build a comprehensive, open-source database of heritable genetics and patient-reported data in lung cancer
From
23andMe, Inc.
Via
GlobeNewswire
23ANDME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates 23andMe Holding Co. - ME
July 19, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel
June 28, 2024
From
23andMe, Inc.
Via
GlobeNewswire
23andMe Launches New Genetic Report on Bipolar Disorder
June 05, 2024
Provides 23andMe+ Premium members with insight into their likelihood of developing the serious mental health illness based on thousands of genetic variants
From
23andMe, Inc.
Via
GlobeNewswire
23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community
June 04, 2024
Study aims to fill research gap and empower people through access to information about their health
From
23andMe, Inc.
Via
GlobeNewswire
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting
June 03, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history
May 29, 2024
Findings from 23andMe research on Parkinson’s disease published in Brain
From
23andMe, Inc.
Via
GlobeNewswire
23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
May 23, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals
May 14, 2024
Lemonaid Health will offer customers more affordable access to fast-acting branded ED medication that works as quickly as 15 minutes prior to sexual activity
From
23andMe, Inc.
Via
GlobeNewswire
23andMe to Report Q4 and Full Year FY2024 Financial Results
May 09, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Potter Handy Law Firm Represents Nearly 5,000 Clients in 23andMe Data Breach Case
April 30, 2024
From
Potter Handy LLP
Via
Business Wire
23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024
Data from neuroendocrine and ovarian cancer patient cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presented
From
23andMe, Inc.
Via
GlobeNewswire
23andMe announces CEO’s intention to pursue a potential take-private
April 18, 2024
From
23andMe, Inc.
Via
GlobeNewswire
23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
April 05, 2024
From
23andMe, Inc.
Via
GlobeNewswire
23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
March 20, 2024
From
23andMe, Inc.
Via
GlobeNewswire
23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago
March 19, 2024
Built upon peer-reviewed published science, the Historical Matches feature weaves customers’ ancestral connections into the story of human history and migration
From
23andMe, Inc.
Via
GlobeNewswire
23andMe Launches New Genetic Reports on Common Forms of Cancer
March 06, 2024
23andMe customers can now gain deeper insight into their likelihood of developing breast, colorectal, and prostate cancer through new reports based on polygenic risk scores (PRS) developed by 23andMe
From
23andMe, Inc.
Via
GlobeNewswire
23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
March 05, 2024
23andMe to give an oral presentation on the genetic signature of ULBP6, the target of 23ME-01473, along with poster presentations of the biology of ULBP6 and mechanism of 23ME-01473, and new...
From
23andMe, Inc.
Via
GlobeNewswire
23andMe Reports Third Quarter Fiscal 2024 Financial Results
February 07, 2024
Announced new non-exclusive data license with GSK, introduced 23andMe Total Health™, and received FDA clearance for IND on novel, dual-mechanism immuno-oncology asset 23ME-1473
From
23andMe, Inc.
Via
GlobeNewswire
23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
January 31, 2024
From
23andMe, Inc.
Via
GlobeNewswire
23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay
January 30, 2024
“Seat 16” program allows audiences to share the critically acclaimed film with teens across the country
From
23andMe, Inc.
Via
GlobeNewswire
23andMe to Report FY2024 Third Quarter Financial Results
January 24, 2024
From
23andMe, Inc.
Via
GlobeNewswire
23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohorts
December 19, 2023
From
23andMe, Inc.
Via
GlobeNewswire
23andMe Reports Second Quarter Fiscal 2024 Financial Results
November 08, 2023
Announced launch of new 23andMe+ Total Health™ membership, signed new $20M non-exclusive data license with GSK, continued progress on improving product margin
From
23andMe, Inc.
Via
GlobeNewswire
23andMe Launches Total Health™, its Comprehensive, Prevention-Based Health Membership
November 07, 2023
The Company’s first-of-its-kind health membership combines exome sequencing, blood testing and direct access to clinicians trained in genetics for ongoing disease prevention and early detection
From
23andMe, Inc.
Via
GlobeNewswire
23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
November 06, 2023
From
23andMe, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.